


OABK hydrochloride

Cat. No.:	HY-100825		
CAS No.:	1984862-48-7		
Molecular Formula:	C ₁₄ H ₂₀ ClN ₅ O ₄		
Molecular Weight:	357.79		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (69.87 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.7949 mL	13.9747 mL	27.9494 mL
		5 mM	0.5590 mL	2.7949 mL	5.5899 mL
10 mM		0.2795 mL	1.3975 mL	2.7949 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.99 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	OABK hydrochloride is a small-molecule switch that can be used to control protein activity.
In Vitro	A small-molecule switch for the activation of protein function through the site-specific incorporation of an ortho-azidobenzoyloxycarbonyl lysine (OABK). The amino acid OABK is synthesized readily in three steps from 2-azidobenzyl alcohol via a succinimidyl carbonate. Deprotection results in the formation of lysine and, when OABK is incorporated into a protein, the formation of active wild-type protein. Genetically encoded OABK in conjunction with small-molecule activation allows for the conditional regulation of intracellular protein maturation. Incorporation of OABK (0.5 mM) at position K85 of EGFP inhibits fluorophore formation until the native lysine is generated through small-molecule activation (the model is

based on Protein Data Bank (PDB). Introducing OABK at position K206 inhibits FLuc enzymatic activity by restricting the access of adenosine triphosphate (ATP) to the active site, until the enzyme is deprotected and activated through phosphine treatment. The incorporation of OABK into FLuc blocks the luciferase activity in the absence of small-molecule activation, as determined by a Bright-Glo luciferase assay^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

HEK293T cells are plated at 100,000 cells per well (400 μ L) into a poly-D-lysine-coated eight-well chamber slide. At 75% confluency, cells are co-transfected with pEGFP-K85TAG-mCherry or pEGFP-K29TAG-SatB1-mCherry and pOABKRS-4PyIT (200 ng of each plasmid) using linear PEI (3 μ L, 0.323 mg/mL). After 20 hours of incubation at 37°C and 5% CO₂ in DMEM with 10% FBS in the presence of OABK (0.25 mM), the cells are washed three times with phenol-red-free DMEM (200 μ L), followed by three hours of incubation to remove any non-incorporated OABK. Before small-molecule activation, the cells are focused using the Texas Red channel, and imaged with a Nikon A1 confocal microscope (\times 40 oil objective, \times 2 zoom, fluorescein isothiocyanate (ex=488 nm) and Texas Red (ex=560 nm) channels)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Luo J, et al. Small-molecule control of protein function through Staudinger reduction. Nat Chem. 2016 Nov;8(11):1027-1034.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA